BD (Becton, Dickinson and Company), a global leader in medical technology, will highlight its newest innovations in drug delivery systems at CPHI Milan 2024 on October 8th and 9th in Milan, Italy. The event is a premier global platform for pharmaceutical professionals, focusing on innovations in drug delivery and packaging systems. This year's showcase at booth #20A65 will emphasize BD’s continued commitment to advancing healthcare through cutting-edge drug delivery solutions and feature an array of innovative products designed to meet the growing demands of pharmaceutical and biotech industries across a range of therapeutic areas.
Featured products include:
- BD iDFill™ Individual Prefillable Syringe Identification: A Radio Frequency Identification (RFID)-based solution for prefillable syringes (PFS) aimed at enhancing efficiency and improving traceability during fill-and-finish operations. BD iDFill™ is also a finalist for the 2024 CPHI Manufacturing Excellence Award.
- BD Neopak™ XtraFlow™ Glass Prefillable Syringe: Designed for subcutaneous delivery of high-viscosity biologics with a shorter 8mm needle length and thinner wall technology. BD’s product demonstration booth will offer attendees an interactive experience, showcasing how BD Neopak™ XtraFlow™ Glass Prefillable Syringe is allowing drug developers to Flow Beyond Limits.
- BD SCF™ PremiumCoat® 1-3mL Plunger Stopper: Engineered to support the subcutaneous injection of complex biologics and viscous solutions through reduced glide force and glide force variability and guaranteeing container closure integrity.
"At BD, our mission is to support the global health community with drug delivery solutions that are as innovative as they are reliable," said Fernand Goldblat, VP/GM BD Medical-Pharmaceutical Systems, PFS platform. "Our presence at CPHI Milan reaffirms our commitment to collaboration and partnership with biopharmaceutical companies to bring next-generation solutions to market."
BD will also display other products, including BD Effivax™ Glass Prefillable Syringe for vaccines, BD Libertas™ Wearable Injector, BD Evolve™ On-body Injector wearable solutions, BD Physioject™ Disposable Autoinjector, and BD Vystra™ Disposable Pen for biologics. These products and innovative solutions exemplify BD's leadership in offering a broad range of injection solutions to enable delivery of vaccines, treatments such as GLP-1s, and other next-generation treatments for chronic disease.